PTO/SB/08B (01-08)

Approved for use through 02/29/2008. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Un	der the Paperwork Red	uction A	ct of 1995, no persons ar	e required to respond to a collection	of information unless it contains a valid OMB control	lnumber	
Substitu	te for form 1449/PTO			Complete if Known			
INFORMATION DISCLOSURE				Application Number	10/720,134		
				Filing Date	November 25, 2003		
				First Named Inventor	Thomas P. Jerussi		
				Art Unit	1621		
				Examiner Name	Paul A. Zucker		
Sheet	1	of	1	Attorney Docket Number	4821-531-999		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/PZ/	1	Eric A. MUTH, et al., Clinical Experience with Effexor (Venlafaxine HCl): Meet the Experts, May 21, 1994, Philadelphia, PA	

Signature Considered C

Date

06/05/2008

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

/Paul Zucker/

Examiner

considered. Include Copy of this form wan next communication to approach to.

Applicant is unjust carbon designation untrafel (optional). Applicant is to place a check may here it Explicit injusping. Transition is satisfied.

1 Applicant is unjust carbon designation and the satisfied of the sat